JP2004522714A5 - - Google Patents

Download PDF

Info

Publication number
JP2004522714A5
JP2004522714A5 JP2002544073A JP2002544073A JP2004522714A5 JP 2004522714 A5 JP2004522714 A5 JP 2004522714A5 JP 2002544073 A JP2002544073 A JP 2002544073A JP 2002544073 A JP2002544073 A JP 2002544073A JP 2004522714 A5 JP2004522714 A5 JP 2004522714A5
Authority
JP
Japan
Prior art keywords
patient
methylsulfonyl
pyrimidin
fluorophenyl
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002544073A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004522714A (ja
JP5062940B2 (ja
Filing date
Publication date
Priority claimed from GBGB0028429.9A external-priority patent/GB0028429D0/en
Application filed filed Critical
Publication of JP2004522714A publication Critical patent/JP2004522714A/ja
Publication of JP2004522714A5 publication Critical patent/JP2004522714A5/ja
Application granted granted Critical
Publication of JP5062940B2 publication Critical patent/JP5062940B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002544073A 2000-11-22 2001-11-16 ヘテロ型家族性高コレステロール血症の治療におけるロスバスタチン(zd−4522)の使用 Expired - Lifetime JP5062940B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0028429.9A GB0028429D0 (en) 2000-11-22 2000-11-22 Therapy
GB0028429.9 2000-11-22
PCT/GB2001/005041 WO2002041895A1 (en) 2000-11-22 2001-11-16 Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009255813A Division JP2010031047A (ja) 2000-11-22 2009-11-09 ヘテロ型家族性高コレステロール血症の治療におけるロスバスタチン(zd−4522)の使用

Publications (3)

Publication Number Publication Date
JP2004522714A JP2004522714A (ja) 2004-07-29
JP2004522714A5 true JP2004522714A5 (enExample) 2005-12-22
JP5062940B2 JP5062940B2 (ja) 2012-10-31

Family

ID=9903629

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002544073A Expired - Lifetime JP5062940B2 (ja) 2000-11-22 2001-11-16 ヘテロ型家族性高コレステロール血症の治療におけるロスバスタチン(zd−4522)の使用
JP2009255813A Pending JP2010031047A (ja) 2000-11-22 2009-11-09 ヘテロ型家族性高コレステロール血症の治療におけるロスバスタチン(zd−4522)の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009255813A Pending JP2010031047A (ja) 2000-11-22 2009-11-09 ヘテロ型家族性高コレステロール血症の治療におけるロスバスタチン(zd−4522)の使用

Country Status (34)

Country Link
US (1) US6858618B2 (enExample)
EP (1) EP1339409B1 (enExample)
JP (2) JP5062940B2 (enExample)
KR (1) KR100815042B1 (enExample)
CN (1) CN1268339C (enExample)
AR (1) AR031766A1 (enExample)
AT (1) ATE394103T1 (enExample)
AU (2) AU2002214165B9 (enExample)
BG (1) BG66009B1 (enExample)
BR (1) BR0115511A (enExample)
CA (1) CA2429263C (enExample)
CY (1) CY1110428T1 (enExample)
CZ (1) CZ301583B6 (enExample)
DE (1) DE60133921D1 (enExample)
DK (1) DK1339409T3 (enExample)
EE (1) EE05507B1 (enExample)
ES (1) ES2305118T3 (enExample)
GB (1) GB0028429D0 (enExample)
HU (1) HUP0301380A3 (enExample)
IL (2) IL155919A0 (enExample)
IS (1) IS6819A (enExample)
MX (1) MXPA03004336A (enExample)
MY (1) MY134902A (enExample)
NO (1) NO326245B1 (enExample)
NZ (1) NZ525754A (enExample)
PL (1) PL365386A1 (enExample)
PT (1) PT1339409E (enExample)
RU (1) RU2294744C2 (enExample)
SI (1) SI1339409T1 (enExample)
SK (1) SK6212003A3 (enExample)
TW (1) TWI238720B (enExample)
UA (1) UA75614C2 (enExample)
WO (1) WO2002041895A1 (enExample)
ZA (1) ZA200303636B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
SG182849A1 (en) * 2003-04-25 2012-08-30 Gilead Sciences Inc Antiviral phosphonate analogs
EP1620109A2 (en) * 2003-04-25 2006-02-01 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7396927B2 (en) * 2003-08-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US7432273B2 (en) * 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
WO2005051921A1 (en) 2003-11-24 2005-06-09 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
CN1894221B (zh) * 2003-12-02 2012-08-08 特瓦制药工业有限公司 用于表征罗苏伐他汀的参照标准品
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
WO2005115377A1 (en) * 2004-05-26 2005-12-08 Kgk Synergize Inc Functional foods comprising flavonoids and tocotrienols and methods thereof
WO2006017357A1 (en) * 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
PT2258376T (pt) 2004-07-27 2019-05-31 Gilead Sciences Inc Análogos fosfonatados de compostos inibidores do vih
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
TWI345562B (en) 2005-02-22 2011-07-21 Teva Pharma Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
KR20070062996A (ko) * 2005-08-16 2007-06-18 테바 파마슈티컬 인더스트리즈 리미티드 결정성 로수바스타틴 중간체
US9427437B2 (en) 2008-01-31 2016-08-30 The Trustees Of The University Of Pennsylvania Hypercholesterolemia and tendinous injuries
US8383614B2 (en) * 2008-01-31 2013-02-26 The Trustees Of The University Of Pennsylvania Hypercholestrolemia and tendinous injuries
EP2298745B1 (en) 2008-05-27 2014-09-03 Changzhou Pharmaceutical Factory Preparation method of rosuvastatin calcium and its intermediates
BRPI0915878A2 (pt) 2008-07-08 2015-11-03 Gilead Sciences Inc sais ou hidratos de compostos inibidores de hiv, seu uso e composição farmacêutica que os compreende
ES2795450T3 (es) 2012-09-17 2020-11-23 Madrigal Pharmaceuticals Inc Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
PT3661937T (pt) 2017-08-01 2021-09-24 Gilead Sciences Inc Formas cristalinas de ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-il)-4-fluoro-2,5-dihidrofurano-2-il)oxi)metil)(fenoxi)fosforil)-l-alaninato de etil (gs-9131) para tratamento de infeções virais
KR20220029584A (ko) 2019-05-27 2022-03-08 이매틱스 유에스 인코포레이티드 바이러스 벡터 및 입양 세포 요법에서 그 사용
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
WO2022165227A1 (en) * 2021-02-01 2022-08-04 Madrigal Pharmaceuticals, Inc. Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease
KR20260072167A (ko) 2024-11-13 2026-05-20 주식회사 종근당 텔미사르탄, 에스암로디핀, 로수바스타틴 및 에제티미브를 포함하는 약제학적 복합제제

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2051907C1 (ru) * 1989-05-22 1996-01-10 Сандос АГ Способ получения 7-замещенной гептен-6-овой кислоты
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU6294501A (en) * 2000-09-20 2002-04-02 Rtp Pharma Inc Spray drying process and compositions of fenofibrate

Similar Documents

Publication Publication Date Title
JP2022009125A5 (enExample)
RU2003114300A (ru) Применение розувастатина (zd-4522) в лечении гетерозиготной семейной гиперхолестеринемии
JP2011500851A5 (enExample)
JP2005515966A5 (enExample)
JP2005520778A5 (enExample)
JP2001510795A5 (enExample)
JP2015524444A5 (enExample)
RU2012110592A (ru) Соединения и способ снижения мочевой кислоты
JP6068765B2 (ja) 薬学的複合製剤
JP2002528502A5 (enExample)
JP2006518731A5 (enExample)
JP2005508963A5 (enExample)
JP2004519424A5 (ja) インシュリン分泌促進剤およびHMG−Co−Aレダクターゼ阻害剤およびACE阻害剤から選択される活性成分を含む組み合わせ
WO2009048289A2 (en) Pharmaceutical composition for treating hepatitis c virus infection comprising hmg-coa reductase inhibitor and bile acid
JP2002518449A (ja) 高血中コレステロールを治療する組成物および方法
JP2005512946A5 (enExample)
JP2013536206A5 (enExample)
RU2013112890A (ru) Терапевтическое применение 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
JP2002536333A5 (enExample)
JP2009539877A5 (enExample)
RU2004112422A (ru) Роувастатин в преддеменционных состояниях
HK1040924A1 (zh) 降膽固醇劑的應用
JP2005505605A5 (enExample)
TW200951117A (en) Combination of dronedarone with at least one diuretic, therapeutic application thereof
DE60019968D1 (de) Verwendung von gepirone metabolite zur erstellungs eines medicaments zur behandlung von neurologischer krankheiten